 This is an open-label rollover study of Study WRI-GEV-007, which evaluates SV-BR-1-GM in metastatic or locally recurrent breast cancer patients. Patients who demonstrate progressive disease on Study WRI-GEV-007 will be eligible to enroll in this study, which will evaluate SV-BR-1-GM in combination with pembrolizumab Keytruda if their tumors express PD-L1 or PD-L2, or in combination with ipilimumab Yervoy if their tumors do not express PD-L1 or PD-L2. Treatment cycles will be every 3 weeks with evaluations for tumor progression or response every 8-12 weeks. 